Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026
Wolfgang Miesbach/LinkedIn, Giancarlo Castaman/Panorama della Sanita
Apr 20, 2026, 15:03

Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”WFH 2026 World Congress, Kuala Lumpur.

Today, Giancarlo Castaman tackled one of the most underappreciated challenges in haemophilia care: what do we do when a patient on non-factor therapy (NFT) needs emergency surgery?

As emicizumab, concizumab, marstacimab and fitusiran reach more patients, perioperative scenarios are becoming increasingly complex – and in an emergency, the stakes could not be higher.

 Emicizumab

  • rFVIIa preferred over aPCC – aPCC at >100 U/kg for ≥24h carries TMA/thrombosis risk (HAVEN 1)
  • 233 surgeries in HAVEN 1–4: 83% major cases managed with CFC/BPA, 80% without post-op bleeding. No deaths, no thrombosis, no new FVIII inhibitors
  • Real-world data from Florence (75 surgeries) confirm these results
  • Critical: aPTT and one-stage FVIII assays uninterpretable on emicizumab – only FVIII chromogenic assay with bovine reagents is reliable

Concizumab (Explorer 7/8)

  • Stop ≥4 days pre-op for major surgery, continue for minor procedures – 44 surgeries, no safety signals

Marstacimab
Stop 8–11 days pre-op for major surgery — 25 surgeries incl. one urgent orthopedic case, no safety issues

Fitusiran

  • AT supplementation + low-dose CFC – 78% reduction in CFC need across 60 surgeries
  • Two post-op DVTs: thrombotic vigilance remains mandatory

Therefore, NFTs do not eliminate the need for replacement therapy.

Structured guidance exists for emicizumab – for newer rebalancing agents, data granularity remains insufficient and management must be individualized.

The haemophilia treatment centre, its expertise and close patient follow-up remain irreplaceable.”

Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026

Stay updated with Hemostasis Today.

bleeding disorders Concizumab DVT Emicizumab Fitusiran HAVEN 1 Health Hematology Hemostasis Hemostasis News Hemostasis Today Marstacimab Medicine NFT Non-factor Therapy WFH 2026 Wolfgang Miesbach
NewsFeed